Efficacy and safety of tocilizumab in pediatric autoimmune disorders

Abstract

Pediatric autoimmune disorders present unique challenges in management due to their diverse clinical manifestations and the long-term consequences of treatment. Tocilizumab, an anti-interleukin-6 (IL-6) receptor monoclonal antibody, has emerged as a promising therapeutic agent in treating various autoimmune conditions in children, including Juvenile Idiopathic Arthritis (JIA) and systemic lupus erythematosus (SLE). This review aims to provide a comprehensive analysis of the efficacy and safety of Tocilizumab in pediatric autoimmune disorders, focusing on clinical outcomes, adverse effects, and long-term safety data.